A retrospective cohort design and data from 2 large integrated US health care claims repositories were used. The 2 repositories-the Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases, and the IMS LifeLink PharMetrics Health Plan Claims Database-both comprise medical (ie, facility and professional service) and outpatient pharmacy claims from a large number of participating health plans. Although lacking clinical richness, these databases provide access to the health care experience (across the continuum of care settings) of tens of millions of persons over a multiyear period, and thus contain information on large numbers of patients with specific cancer diagnoses who are treated with specific chemotherapy regimens. Data for the current study spanned the period from January 1, 2003 through December 31, 2012.
The MarketScan Database includes information (primarily) from employer-sponsored plans throughout the United States that provide health benefits to more than 15 million persons annually, including employees, their spouses, and their dependents, 10% of whom are aged 65 years or older. The LifeLink Database includes information from more than 75 US private health plans providing health care coverage to a geographically diverse population of more than 15 million persons annually; 4% of plan members are 65 years of age or older.
Data available from each facility and professional-service claim include dates and places of service, diagnoses, procedures performed/services rendered, and quantity of services (professional-service claims). Data available for each outpatient pharmacy claim include the drug (class) dispensed, dispensing date, quantity dispensed, and number of days supplied. Medical and pharmacy claims also include amounts paid (ie, reimbursed) by health plans and patients to health care providers for services rendered. Selected demographic and eligibility information, including age, sex, geographic region of residence, and dates of plan eligibility, is also available. All data in each database can be arrayed to provide a detailed chronology of medical and pharmacy services used by each plan member over time.
The study databases were deidentified before their release to study investigators, as set forth in the corresponding Data Use Agreements. The study databases have been evaluated and certified by independent third parties to be in compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 statistical deidentification standards and to satisfy the conditions set forth in Sections 164.514 (a)-(b)1ii of the HIPAA Privacy Rule regarding the determination and documentation of statistically deidentified data. Use of the study databases for health services research is therefore fully compliant with the HIPAA Privacy Rule and federal guidance on Public Welfare and the Protection of Human Subjects (USDHHS 2013). 
Source and Study Populations
The source population comprised all patients aged 18 years or older who, between July 1, 2003, and June 30, 2012, initiated chemotherapy for solid tumors or hematologic malignancy. For each patient in the source population, each unique observed course of chemotherapy was identified, as was each cycle within each of these courses. Patients in the source population were stratified into subgroups based on primary cancer type, presence of metastatic disease, and chemotherapy regimen. From the source population, patients who began treatment with chemotherapy regimens that were classified as "low" or "intermediate"-or unclassified-in terms of associated risk for febrile neutropenia (FN) in guidelines for colony-stimulating factor (CSF) use were selected for inclusion in the study population (NCCN, ). Regimen-specific subgroups including fewer than 3,500 patients were excluded from consideration. Only the first course of chemotherapy with a regimen of interest was considered in analyses (because prior chemotherapy exposure and administration of subsequent courses triggered by suboptimal tumor response or disease progression/recurrence may impact FN risk, and dose delays/reductions are more common in subsequent courses of chemotherapy).
Patients With Cancer Receiving Chemotherapy
Receipt of chemotherapy was ascertained based on the presence of 1 or more encounters for a chemotherapy drug or administration thereof, which was identified using Health Care Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and UB-92 codes. Evidence of initiation of a new course of chemotherapy was based on the earliest encounter for chemotherapy during the study period that was preceded by a 60-day or longer period without any other encounter for chemotherapy.
Among identified patients, we further selected those with evidence of primary solid tumors or hematologic malignancy, as indicated by 2 or more encounters (at least 7 days apart) with a qualifying 3-digit ICD-9-CM diagnosis code (see supplemental eAppendix 3) during the period beginning 30 days before the date of chemotherapy initiation and ending 30 days thereafter. Presence of metastases was identified based on 1 or more diagnosis codes (ICD-9-CM 196-198) on inpatient claims or 2 or more diagnosis codes on outpatient claims (excluding those for laboratory services) on different days during the 6-month period before chemotherapy initiation. Patients who had evidence of metastatic disease but did not have an identifiable primary tumor site were not included in the study population.
Chemotherapy Courses, Cycles, and Regimens
For each patient receiving chemotherapy, each unique cycle within each course of chemotherapy was identified. The first chemotherapy cycle (of the first course) was defined as beginning with the date of initiation of chemotherapy and ending with the first service date for the next administration of chemotherapy (as evidenced by an encounter with a corresponding HCPCS or ICD-9-CM) occurring at least 7 days-but no more than 59 days-after the date of chemotherapy initiation. If a second chemotherapy cycle did not commence before day 60, or if evidence was seen that radiation therapy was received (based on encounters with relevant HCPCS, ICD-9-CM, or UB-92 codes) during this period, both the first cycle of chemotherapy and the course of chemotherapy were considered to have been completed 35 days after the beginning of the cycle or on the day before initiation of radiation therapy, whichever occurred first. The second and all subsequent cycles of chemotherapy, and subsequent courses of chemotherapy, if any, during the period of interest, were similarly defined. Chemotherapy courses, and the cycles therein, thus were characterized based on observed patterns of administration using information captured in claims, including corresponding procedure codes and dates of service, and clinical expertise regarding the regimens and their patterns of use in clinical practice. Only myelosuppressive chemotherapy agents were considered in characterizing courses and cycles therein.
Chemotherapy regimens were ascertained based on a review of all HCPCS level II codes for parenterally administered antineoplastic agents (myelosuppressive and nonmyelosuppressive) on claims with service dates within 6 days of the start of each cycle of chemotherapy. Regimens were categorized based on the specific combination of agents during the course and first-cycle periodicity (eg, weekly, once every 2 weeks, once every 3 weeks, monthly).
Schematic of chemotherapy course. In this example, the patient received only 2 cycles, all chemotherapy (chemotx) was administered on cycle day 1, both cycles included pegfilgrastim prophylaxis (PEG-P) on cycle day 2, and the cycle periodicity was every 3 weeks. 
Period for Identifying

Exclusion Criteria
Patients were excluded from the source population if there was evidence of 2 or more primary cancers (solid or blood) within (ie, ±) 30 days of their index date. However, patients who had evidence of 2 (or more) primary cancers (eg, breast cancer and lung cancer) and evidence of metastatic disease to 1 (or more) of these sites (eg, lung cancer) were classified as having a single primary tumor, and thus were retained in the study population (with the assumption that metastatic disease was miscoded as a primary malignancy). Patients also were excluded from the source population if there were any gaps in their eligibility for comprehensive medical and drug benefits during the 6-month ("pretreatment") period before initiation of chemotherapy. Abscess of lung and mediastinum 522.5
Periapical abscess without sinus 522.7
Periapical abscess with sinus 526.4
Inflammatory conditions of the jaw 527. 3 Abscess of the salivary glands 528. 3 Cellulitis and abscess of oral soft tissue 540
Acute appendicitis 541
Appendicitis not otherwise specified 542
Other appendicitis 562.01
Diverticulitis of the small intestine without hemorrhage 562. 03 Diverticulitis of the small intestine with hemorrhage 562.11
Diverticulitis of colon without hemorrhage
Characteristics described below represent many of those listed by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors as important risk factors for febrile neutropenia (FN) (to view the most recent version of these NCCN Guidelines, visit NCCN.org). Demographic characteristics were available for nearly all study subjects. All other characteristics were defined based on the presence of specific data (eg, diagnosis codes, procedure codes); the absence of these data are assumed to indicate the absence of the characteristic captured by the variable.
Patient Characteristics
Patient, cancer, and treatment characteristics included age; sex; presence of selected chronic comorbidities (cardiovascular disease, diabetes, liver disease, lung disease, renal disease, osteoarthritis, rheumatoid disease, thyroid disorder); body weight/nutritional status (obesity, underweight, malnutrition); proxies for health status (hospice/skilled nursing facility care) and physical function (use of hospital bed, supplemental oxygen, walking aid, wheelchair); use of immunosuppressive therapy; history of blood disorders (anemia, neutropenia, other), infection, recent surgery, hospitalization (all-cause and FN-related, respectively), chemotherapy, and radiation therapy; total health care expenditures in the baseline period; presence of metastatic disease; and calendar year of chemotherapy initiation. Age was assessed as of the first day of the first cycle of chemotherapy in the course. All of other risk factors (except for recent surgery and radiation therapy) were assessed during the 12-month period before the first day of the chemotherapy course; recent surgery was assessed during the 30-day prechemotherapy period, and radiation therapy was assessed during the 6-month prechemotherapy period. Chronic comorbidities were identified based on 1 or more diagnosis codes on inpatient claims, 2 or more diagnosis codes on outpatient claims (excluding those for laboratory services) on different days, 1 or more procedure codes, and 1 or more drug codes, as appropriate. Blood disorders and infections were identified on the basis of 1 or more diagnosis codes (on inpatient and/or outpatient claims) and 1 or more drug codes, as appropriate.
Use of Colony-Stimulating Factor Prophylaxis
Use of colony-stimulating factor (CSF; ie, filgrastim, pegfilgrastim, or sargramostim) was characterized in terms of the reason, timing, and duration of administration, on a cycle-specific basis. Reason for use of these agents was characterized based on the timing of receipt within the chemotherapy course and cycles, as follows:
1. Primary prophylaxis: receipt on or before day 5 of cycle 1; 2. Secondary prophylaxis: first receipt (as prophylaxis) on or before day 5 of cycle 2 or a subsequent cycle (irrespective of prior receipt of CSF as treatment); and 3. Treatment: first receipt (in a given cycle) anytime after cycle day 5 or receipt after the end of prophylaxis (defined as a gap of >3 days).
Timing of use of these agents, as prophylaxis and treatment, was depicted based on the day of first receipt during the cycle of administration. Duration of use of filgrastim and sargramostim, as prophylaxis and treatment, was characterized based on temporal patterns of administration among the subgroup of patients with corresponding medical claims only (precise dates of administration cannot be ascertained based on pharmacy claims). 
